Overview
Compare with Longevity Health Holdings, Inc., Meiwu Technology Co Ltd or Orion Bliss Corp., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Franchise Fees brought in 60% of the revenue Park Ha Biological Technology Co., Ltd. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Franchise Fees | $1.8M | $1.7M | $1.5M |
| Products Sales Nonfranchisees | $302.5K | $355.8K | $535.8K |
| Product Sales Franchisees | $346.2K | $351.4K | $478.3K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue6¢$142.5K
- Research and development9¢$238.2K
- Other costs74¢$1.9M
- Income tax11¢$280.6K
Out of $2.5M in revenue.2 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Kept or used elsewhere100¢$85.9K
Out of $85.9K of cash from operations.2
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-10-31 | 2024-10-31 | 2023-10-31 |
|---|---|---|---|
| Revenues, net | $2.5M | $2.4M | $2.5M |
| Cost of revenues | $142.5K | $195.3K | $311.0K |
| Gross profit | $2.4M | $2.2M | $2.1M |
| Selling and marketing expenses | $625.3K | $361.3K | $299.6K |
| General and administrative expenses | $25.5M | $814.9K | $485.0K |
| Research and development expenses | $238.2K | $36.7K | $30.9K |
| Allowance for expected credit losses | $184.2K | $179.9K | $152.1K |
| Total operating expenses | $26.5M | $1.4M | $967.6K |
| Operating (loss) income | -$24.1M | $793.7K | $1.2M |
| Other income (expense) | $58.7K | -$1.1K | -$575 |
| Interest income | $6.1K | $783 | $1.6K |
| Interest expense | -$41 | ||
| Total other income (expenses) | $64.8K | -$293 | $1.0K |
| (Loss) income before income tax | -$24.1M | $793.4K | $1.2M |
| Income tax expenses (benefits) | $280.6K | $314.9K | $329.5K |
| Net (loss) income | -$24.4M | $478.6K | $852.0K |
| Foreign currency translation adjustments | -$7.0K | $14.6K | -$28.1K |
| Total comprehensive (loss) income | -$24.4M | $493.1K | $823.9K |
| Ordinary shares basic (in Dollars per share) | -$41.38 | $0.96 | $1.70 |
| Ordinary shares diluted (in Dollars per share) | -$41.38 | $0.96 | $1.70 |
| Ordinary shares basic (in Shares) | 588.9K shares | 500.0K shares | 500.0K shares |
| Ordinary shares diluted (in Shares) | 588.9K shares | 500.0K shares | 500.0K shares |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $3.8M | $547.5K | ||
| Accounts receivables, net | $255.8K | $330.9K | ||
| Inventories, net | $75.2K | $71.5K | ||
| Advances to suppliers | $9.4K | $19.2K | ||
| Loans receivable from franchisees, net | $1.0M | $746.0K | ||
| Other receivables and other current assets | $352.6K | $1.1M | ||
| Total current assets | $5.5M | $2.8M | ||
| Property and equipment, net | $158.0K | $104.0K | ||
| Intangible assets, net | $6.6K | $7.6K | ||
| Operating lease right of use asset, net | $180.2K | $70.7K | ||
| Other non-current assets | $105.8K | $56.7K | ||
| Total non-current assets | $450.7K | $239.0K | ||
| TOTAL ASSETS | $6.0M | $3.1M | ||
| Accounts payable | $12.0K | $24.1K | ||
| Taxes payable | $1.4M | $1.0M | ||
| Operating lease liabilities current | $104.3K | $17.6K | ||
| Contract liability | $194.8K | $325.9K | ||
| Accruals and other payables | $188.3K | $155.9K | ||
| Total current liabilities | $1.9M | $1.5M | ||
| Operating lease liabilities non-current | $75.9K | $52.7K | ||
| Total non-current assets | $75.9K | $52.7K | ||
| TOTAL LIABILITIES | $2.0M | $1.6M | ||
| Additional paid in capital | $28.0M | $1.2M | ||
| Statutory reserve | $217.3K | $132.0K | ||
| (Accumulated deficits) Retained earning | -$24.2M | $271.8K | ||
| Accumulated other comprehensive loss | -$66.4K | -$59.4K | ||
| Total Shareholders equity | $4.0M | $1.5M | $1.0M | $150.3K |
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | $6.0M | $3.1M |
| Period ending | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $3.8M | $547.5K | ||
| Accounts receivables, net | $255.8K | $330.9K | ||
| Inventories, net | $75.2K | $71.5K | ||
| Advances to suppliers | $9.4K | $19.2K | ||
| Loans receivable from franchisees, net | $1.0M | $746.0K | ||
| Other receivables and other current assets | $352.6K | $1.1M | ||
| Total current assets | $5.5M | $2.8M | ||
| Property and equipment, net | $158.0K | $104.0K | ||
| Intangible assets, net | $6.6K | $7.6K | ||
| Operating lease right of use asset, net | $180.2K | $70.7K | ||
| Other non-current assets | $105.8K | $56.7K | ||
| Total non-current assets | $450.7K | $239.0K | ||
| TOTAL ASSETS | $6.0M | $3.1M | ||
| Accounts payable | $12.0K | $24.1K | ||
| Taxes payable | $1.4M | $1.0M | ||
| Operating lease liabilities current | $104.3K | $17.6K | ||
| Contract liability | $194.8K | $325.9K | ||
| Accruals and other payables | $188.3K | $155.9K | ||
| Total current liabilities | $1.9M | $1.5M | ||
| Operating lease liabilities non-current | $75.9K | $52.7K | ||
| Total non-current assets | $75.9K | $52.7K | ||
| TOTAL LIABILITIES | $2.0M | $1.6M | ||
| Additional paid in capital | $28.0M | $1.2M | ||
| Statutory reserve | $217.3K | $132.0K | ||
| (Accumulated deficits) Retained earning | -$24.2M | $271.8K | ||
| Accumulated other comprehensive loss | -$66.4K | -$59.4K | ||
| Total Shareholders equity | $4.0M | $1.5M | $1.0M | $150.3K |
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | $6.0M | $3.1M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-10-31 | 2024-10-31 | 2023-10-31 |
|---|---|---|---|
| Net (loss) income | -$24.4M | $478.6K | $852.0K |
| Depreciation and amortization | $109.4K | $22.7K | $20.1K |
| Allowance for credit losses | $184.2K | $179.9K | $152.1K |
| Allowance for Inventory | $12.4K | ||
| Inventory write-off | $1.4K | $16.0K | $1.2K |
| Deferred tax benefits | -$26.7K | -$21.5K | -$33.7K |
| Non-cash lease expenses | $37.4K | $30.4K | $45.9K |
| Share-based Compensation Expense | $24.1M | ||
| Other non-cash operating expense | $153.8K | ||
| Accounts receivable | $72.0K | -$98.7K | -$337.7K |
| Inventories | -$17.5K | $10.5K | -$2.8K |
| Advances to suppliers | $9.7K | $76.9K | $9.0K |
| Other receivables and other current assets | -$324.3K | -$36.9K | -$265.8K |
| Operating advance payments to related parties | -$35 | ||
| Other non-current assets | -$20.3K | $9.6K | $178.0K |
| Accruals and other payables | -$1.8K | $27.4K | $35.3K |
| Accounts payable | -$11.9K | -$176.1K | $69.4K |
| Taxes payable | $369.2K | $403.4K | $437.3K |
| Contract liability | -$129.4K | $68.7K | -$989.1K |
| Operating lease liabilities | -$37.0K | -$30.4K | -$44.7K |
| Net cash provided by operating activities | $85.9K | $960.5K | $126.5K |
| Purchase of equipment and intangible assets | -$88.8K | -$85.6K | -$22.7K |
| Loans to franchisees | -$1.1M | -$1.2M | -$311.1K |
| Loan repayment from franchisees | $605.0K | $810.7K | $1.4M |
| Loans to the third party | -$6.0M | ||
| Loans repayment from the third party | $6.0M | ||
| Advance to related parties | -$28.3K | -$20.0K | |
| Repayment from related parties | $14.1K | $31.5K | $15.6K |
| Net cash (used in) provided by investing activities | -$572.9K | -$508.1K | $1.0M |
| Proceeds from shareholders contribution of capital | $500 | $38.3K | |
| Proceeds from issuance of shares | $4.3M | ||
| Borrowing from related parties | $6.9K | $4.2K | $60.9K |
| Repayment to related parties | -$73.3K | -$776.1K | |
| IPO Cost | -$549.1K | -$888.8K | |
| Net cash provided by (used in) financing activities | $3.7M | -$957.4K | -$676.9K |
| Net increase (decrease) in cash | $3.2M | -$505.1K | $473.0K |
| Effect of exchange rate changes on cash | -$8.4K | $18.9K | -$14.1K |
| Noncash obtained leasehold improvements | $72.9K | ||
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | $144.9K | $65.9K | $52.7K |
No quarter-by-quarter statement was filed.
Compare Park Ha Biological Technology Co., Ltd. with another company
Corporate structure
Park Ha Biological Technology Co., Ltd. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Park Ha Biological Technology Co., Ltd.
- Li (forest) Wang Filed SCHEDULE 13G on Park Ha Biological Technology Co., Ltd., latest Aug 13, 2026
- Chunxin Xia Filed SCHEDULE 13G on Park Ha Biological Technology Co., Ltd., latest Aug 10, 2026
- Hao (mike) Meng Filed SCHEDULE 13G on Park Ha Biological Technology Co., Ltd., latest Aug 10, 2026
- Jie (jessie) Cao Filed SCHEDULE 13G on Park Ha Biological Technology Co., Ltd., latest Aug 10, 2026
- Qi (maxi) Meng Filed SCHEDULE 13G on Park Ha Biological Technology Co., Ltd., latest Aug 10, 2026
- Yajie Ma Filed SCHEDULE 13G on Park Ha Biological Technology Co., Ltd., latest Aug 10, 2026
- Yee Loon Ng Filed SCHEDULE 13G on Park Ha Biological Technology Co., Ltd., latest Aug 10, 2026
- Yingying (kathy) Guo Filed SCHEDULE 13G on Park Ha Biological Technology Co., Ltd., latest Aug 10, 2026
- Park Ha Biological Technology Co., Ltd. Wuxi City, China
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Park Ha Biological Technology Co., Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $435.3K2 Oct 31, 2025 | $271.3K2 Oct 31, 2024 | +60.4% |
| Accumulated depreciation | $277.3K2 Oct 31, 2025 | $167.4K2 Oct 31, 2024 | +65.7% |
| Property and equipment, net | $158.0K2 Oct 31, 2025 | $104.0K2 Oct 31, 2024 | +52.0% |
| Operating-lease assets (leased space) | $180.2K2 Oct 31, 2025 | $70.7K2 Oct 31, 2024 | +154.8% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $3.8M2 Oct 31, 2025 | $547.5K2 Oct 31, 2024 | +591.8% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Intangible assets, net (excluding goodwill) | $6.6K2 Oct 31, 2025 | $7.6K2 Oct 31, 2024 | −12.9% |
| Finite-lived intangibles, gross | $10.1K2 Oct 31, 2025 | $10.1K2 Oct 31, 2024 | 0% |
| Accumulated amortization | $3.5K2 Oct 31, 2025 | $2.5K2 Oct 31, 2024 | +39.9% |
| Finite-lived intangibles, net | $6.6K2 Oct 31, 2025 | $7.6K2 Oct 31, 2024 | −12.9% |
Inventory
Leadership
Who has led Park Ha Biological Technology Co., Ltd., and when. Pick a name to see everywhere that person has worked.
- Chief executive officerXiaoqiu Zhang Apr 7, 2026 to now5
- Chief financial officerXiaoyan Zhu Apr 7, 2026 to now6
Board members and other officers (5)
- CTOXinyu Li Apr 7, 2026 to now7
- Board memberQixiong Sheng Apr 7, 2026 to now8
- Board memberXiaoqiu Zhang Apr 7, 2026 to now5
- Board memberXiaozhong Yu Apr 7, 2026 to now9
- Board memberYanan Shan Apr 7, 2026 to now10
Timeline
- Apr 7, 2026New chief executive Xiaoqiu Zhang becomes CEO5
Filings
97 filings to the SEC since October 2021: 4 annual reports, 8 insider forms, 8 large holders, 77 other. The latest 20:
- Sep 11, 20266-K EDGAR
- Sep 2, 20266-K EDGAR
- Aug 13, 2026SCHEDULE 13G EDGAR
- Aug 10, 2026SCHEDULE 13G EDGAR
- Aug 10, 2026SCHEDULE 13G EDGAR
- Aug 10, 2026SCHEDULE 13G EDGAR
- Aug 10, 2026SCHEDULE 13G EDGAR
- Aug 10, 2026SCHEDULE 13G EDGAR
- Aug 10, 2026SCHEDULE 13G EDGAR
- Aug 10, 2026SCHEDULE 13G EDGAR
- Aug 10, 20263 EDGAR
- Aug 7, 20264 EDGAR
- Aug 3, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Aug 3, 2026S-8 REGISTRATION STATEMENT EDGAR
- Aug 3, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 24, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 13, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 6, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 6, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
- Jul 1, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
The 97 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Li (forest) WangSCHEDULE 13G, 1 filing Aug 13, 202611
- Chunxin XiaSCHEDULE 13G, 1 filing Aug 10, 202612
- Hao (mike) MengSCHEDULE 13G, 1 filing Aug 10, 202613
- Jie (jessie) CaoSCHEDULE 13G, 1 filing Aug 10, 202614
- Qi (maxi) MengSCHEDULE 13G, 1 filing Aug 10, 202615
- Yajie MaSCHEDULE 13G, 1 filing Aug 10, 202616
- Yee Loon NgSCHEDULE 13G, 1 filing Aug 10, 202617
- Yingying (kathy) GuoSCHEDULE 13G, 1 filing Aug 10, 202618
SEC filer profile
How Park Ha Biological Technology Co., Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARPark Ha Biological Technology Co., Ltd.1
- CIK0001986247
- Filer statusNon-accelerated filer an emerging growth company; not a shell company19
- Incorporated inCayman Islands19
- Fiscal year endsOctober 311
- Industry code (SIC)2840 Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business addressNo. 50 Xiuxi Road, 14F, Building 3, Wuxi City, F4 2141351
- Phone8640001275621
- Shares outstanding296,488 Common Class A shares; 381,000 Common Class B shares as of Oct 31, 202519
- AuditorWWC, P.C., San Mateo, California PCAOB ID 1171; no auditor attestation of internal control over financial reporting19
- On EDGAR sinceDec 29, 20231
- Filings97 in all: 6-K (31), CORRESP (9), F-1/A (8), SCHEDULE 13G (8), 3 (7), UPLOAD (6), EFFECT (3), S-8 (3)1
All 22 form types
20-F (2), 20-F/A (2), 424B4 (2), DRS (2), DRS/A (2), DRSLTR (2), F-1 (2), F-3/A (2), 4 (1), 424B5 (1), 8-A12B (1), CERT (1), F-3 (1), FWP (1)
- Latest filingsAnnual report (20-F) Mar 2, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Ordinary Shares, par value $0.001 per share | BYAH | Nasdaq |
From the cover page of the 20-F filed Mar 2, 2026 (Section 12(b) of the Exchange Act).19
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6SEC EDGARXiaoyan Zhu, Chief financial officer
- 7SEC EDGARXinyu Li, CTO
- 8SEC EDGARQixiong Sheng, Board member
- 9SEC EDGARXiaozhong Yu, Board member
- 10SEC EDGARYanan Shan, Board member
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19